[8] Kheradmand E,

Haghjooy-Javanmard S, Dehghani L, Saadatnia M. Polymorphisms at activated protein C cleavage sites of factor V: Are they important in the absence of factor V Leiden?. Iranian Journal of Neurology. 2017;**16**(1):30-33

[9] Chan NC, Eikelboom JW, Weitz JI. Evolving Treatments for Arterial and Venous Thrombosis: Role of the Direct Oral Anticoagulants. Circulation Research. 29 Apr 2016;**118**(9):1409-1424. DOI: 10.1161/CIRCRESAHA.116.306925. PMID: 27126650

[10] Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: Treatment of deep vein thrombosis and pulmonary embolism. Blood Advances. 2020;**4**(19):4693-4738. DOI: 10.1182/ bloodadvances.2020001830

[11] Manojna Konda MD. Hereditary and Acquired Hypercoagulability. Practice Essentials, COVID-19, Pathophysiology. 2021

[12] Nicolaes GAF, Dahlbäck B. Congenital and acquired activated protein C resistance. Seminars in Vascular Medicine. Feb 2003;**3**(1):33- 46. DOI: 10.1055/s-2003-38331. PMID: 15199491

[13] Gupta A, Tun AM, Gupta K, et al. Protein S Deficiency. [Updated 2021 Aug 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; Jan 2022. Available from: https://www.ncbi. nlm.nih.gov/books/NBK544344/

[14] Esmon CT. Protein S and protein C biochemistry, physiology, and clinical manifestation of deficiencies. Trends in Cardiovascular Medicine. 1992;**2**(6):214- 219. DOI: 10.1016/1050-1738(92)90027-P

[15] Armstrong EM, Bellone JM, Hornsby LB, Treadway S, Phillippe HM. Acquired thrombophilia. Journal of Pharmacy Practice. 2014;**27**(3):234-242

[16] Tektonidou MG, Andreoli L, Limper M, et al. EULARrecommendations for the management of antiphospholipid syndrome in adults. Annals of the Rheumatic Diseases. 2019;**78**:1296-1304

[17] Abdol Razak NB, Jones G, Bhandari M, Berndt MC, Metharom P. Cancer-associated thrombosis: An overview of mechanisms, risk factors, and treatment. Cancers (Basel). 2018;**10**(10):380. Published 2018 Oct 11. DOI: 10.3390/cancers10100380

[18] Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrom J. Incidence and mortality of venous thrombosis: A population-based study. Journal of Thrombosis and Haemostasis: JTH. 2007;**5**(4):692-699

[19] Papageorgiou C, Jourdi G, Adjambri E, Walborn A, Patel P, Fareed J, et al. Disseminated intravascular coagulation: An update on pathogenesis, diagnosis, and therapeutic strategies. Clinical and Applied Thrombosis/Hemostasis: Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2018;**24**(suppl. 9):8S-28S

[20] Tuzovic M, Herrmann J, Iliescu C, Marmagkiolis K, Ziaeian B, Yang EH. Arterial thrombosis in patients with cancer. Current Treatment Options in Cardiovascular Medicine. 2018;**20**(5):1-7 [21] Battinelli EM, Marshall A, Connors JM. The role of thrombophilia in pregnancy. Thrombosis. 2013;**2013**: 516420. DOI: 10.1155/2013/ 516420. Epub 2013 Dec 18. PMID: 24455235; PMCID: PMC3880751

[22] Bremme KA. Haemostatic changes in pregnancy. Best Practice & Research. Clinical Haematology. Jun 2003;**16**(2):153-168. DOI: 10.1016/ s1521-6926(03)00021-5

[23] Linkins LA. Heparin induced thrombocytopenia. BMJ. 8 Jan 2015;**350**:g7566. DOI: 10.1136/bmj.g7566. PMID: 25569604

[24] Kichloo A, Dettloff K, Aljadah M, Albosta M, Jamal S, Singh J, et al. COVID-19 and hypercoagulability: A Review. Clinical and Applied Thrombosis Hemostasis. Jan-Dec 2020;**26**:1076029620962853. DOI: 10.1177/1076029620962853. PMID: 33074732; PMCID: PMC7592310

[25] Alquwaizani M, Buckley L, Adams C, Fanikos J. Anticoagulants: A review of the pharmacology, dosing, and complications. Current Emergency and Hospital Medicine Reports. 2013;**1**(2):83- 97. Published 21 Apr 2013. DOI: 10.1007/ s40138-013-0014-6

[26] Krumb E, Hermans C. Primary prophylaxis of venous thromboembolic disease with direct oral anticoagulants in patients with severe inherited thrombophilia. Research and Practice in Thrombosis and Haemostasis. 2021;**5**: 261-264. DOI: 10.1002/rth2.12479

[27] Donald Schreiber MD. Anticoagulation in Deep Venous Thrombosis: Advantages of Anticoagulant Therapy, Initial Anticoagulation Therapy, Long-Term Anticoagulation. 2021

*Anticoagulation in Thrombophilia DOI: http://dx.doi.org/10.5772/intechopen.103038*

[28] Campello E, Spiezia L, Simion C, Tormene D, Camporese G, Valle FD, et al. Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: A prospective cohort study. Journal of the American Heart Association. 2020;**9**(23):e018917. DOI: 10.1161/JAHA.120.018917

[29] Elsebaie MAT, van Es N, Langston A, Büller HR, Gaddh M. Direct oral anticoagulants in patients with venous thromboembolism and thrombophilia: A systematic review and meta-analysis. Journal of Thrombosis and Haemostasis: JTH. 2019;**17**(4):645-656

[30] Kujovich JL. Factor V Leiden Thrombophilia. 14 May 1999 [Updated 2018 Jan 4]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: https://www.ncbi.nlm. nih.gov/books/NBK1368/

[31] Donovan AK, Smith KJ, Ragni MV. Anticoagulation duration in heterozygous factor V Leiden: a decision analysis. Thrombosis Research. 2013;**132**(6):724-728. DOI: 10.1016/j. thromres.2013.09.012. [Epub Sep 16 2013]. PMID: 24112753.

[32] Kujovich JL. Prothrombin Thrombophilia. 2006 Jul 25 [Updated 2021 Feb 4]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: https://www.ncbi.nlm. nih.gov/books/NBK1148/

[33] Bani-Hani S, Siddiqui O, Patel A, Showkat A. C20209T prothrombin gene mutation associated deep venous thrombosis in a hemodialysis Patient. Clinical Nephrology. Case Studies.

2014;**2**:1-4. Published 2014 Jan 15. DOI: 10.5414/CNCS107984

[34] Suneel Movva MD. Antiphospholipid Syndrome Treatment & Management: Medical care, surgical care, consultations. Antiphospholipid Syndrome Treatment & Management: Medical Care, Surgical Care, Consultations. 2021

[35] Del Papa N, Vaso N. Management of antiphospholipid syndrome. Therapeutic Advances in Musculoskeletal Disease. 2010;**2**(4):221-227. DOI: 10.1177/1759720X10365969

[36] Dufrost V, Risse J, Zuily S, Wahl D. Direct oral anticoagulants use in antiphospholipid syndrome: Are these drugs an effective and safe alternative to Warfarin? A systematic review of the literature. Current Rheumatology Reports. 2016;**18**(12):74. DOI: 10.1007/ s11926-016-0623-7

[37] Park J, Lee JM, Lee JS, Cho YJ. Pharmacological and mechanical thromboprophylaxis in critically ill patients: A network meta-analysis of 12 trials. Journal of Korean Medical Science. 2016;**31**(11):1828-1837. DOI: 10.3346/ jkms.2016.31.11.1828

[38] Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: Prevention and treatment in patients with cancer. Blood Advances. 23 Feb 2021;**5**(4):927-974. DOI: 10.1182/bloodadvances.2020003442. Erratum in: Blood Adv. 2021 Apr 13;5(7):1953. PMID: 33570602; PMCID: PMC7903232

[39] Dargaud Y, Rugeri L, Vergnes MC, Arnuti B, Miranda P, Negrier C, et al. A risk score for the management of pregnant women with increased risk of venous thromboembolism: A multicentre prospective study. British Journal of Haematology. 2009;**145**(6):825-835

[40] Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, Blomström-Lundqvist C, Cífková R, De Bonis M, et al. 2018 ESC Guidelines for the Management of Cardiovascular Diseases during Pregnancy: The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal. September 2018;**39**(34), 07:3165-3241. DOI: 10.1093/eurheartj/ ehy340

[41] Lopes RD, de Barros E, Silva P, Furtado R, Macedo A, Bronhara B, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial. Lancet (London, England). 2021;**397**(10291):2253-2263

Section 2
